Longeveron Inc. (NASDAQ:LGVN) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET

Company Participants

Elsie Yau - Stern Investor Relations

Chris Min - Interim Chief Executive Officer & Chief Medical Officer

James Clavijo - Chief Financial Officer

Joshua Hare - Co-Founder, Chief Science Officer & Chairman

Conference Call Participants

Michael Okunewitch - Maxim Group

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Longeveron 2022 Second Quarter Earnings Call. My name is Irene and I will be coordinating this event. [Operator Instructions]

I would now like to turn the conference over to our host, Elsie Yau from Stern Investor Relations. Elsie, please go ahead.

Elsie Yau

Thank you, operator. Good morning, everyone and welcome to Longeveron's second quarter 2022 call. Today we will provide a business update and discuss financial results for the second quarter of 2022. Earlier this morning, we issued a press release with these results, which can be found under the Investor section of our website at www.longeveron.com.

I'm joining the call today by the following members of Longeveron's Management team; Dr. Chris Min, Interim Chief Executive Officer and Chief Medical Officer; Dr. Joshua M. Hare, Co-Founder, Chief Science Officer and Chairman; and James Clavijo, Chief Financial Officer.

Dr. Min will begin with a brief corporate overview, followed by a review of update from Aging Frailty Program, including Longeveron's updated strategy in Japan, and the data from the Phase 1/2 HERA trial. Then Mr. Clavijo will review our 2022 second quarter financial results. Last, we will then open the call for Q&A.

As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussion in our filings with the SEC, including our Annual Report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now, I'd like to turn the call over to Dr. Chris Min, Interim Chief Executive Officer and Chief Medical Officer of Longeveron. Chris?

Chris Min

Thank you, Elsie. Good morning everyone. Welcome to Longeveron's second quarter 2020 business update and financial results call. Longeveron is a leading clinical-stage biotechnology company developing living cell therapies for chronic aging-related diseases and other specific life-threatening conditions.